WADA publishes 2017 Prohibited List

The World Anti-Doping Agency (WADA) has published the 2017 Prohibited List, which will come into force on 1 January 2017. Players, team doctors and officials are encouraged to take note of the changes to the list, and to take any action that may be required to ensure compliance with the list by the date of its entry into force.

The key changes are: 

• Category "S2. Peptide hormones, growth factors, related substances and mimetics"
In order to extend the scope of Erythropoietic Stimulating Agents, GATA inhibitors (e.g. K-11706) and Transforming Growth Factor- β (TGF-β) inhibitors (e.g. sotatercept, luspatercept) have been added.

• Category "S3. Beta-2 agonists"
Examples of selective and non-selective beta-2-agonists have been added – fenoterol, formoterol, higenamine, indacaterol, olodaterol, procaterol, reproterol, salbutamol, salmeterol, terbutaline, and vilanterol. WADA has thus clarified that higenamine is considered to be a prohibited substance.

Dosing parameters of salbutamol have been refined to make it clear that the full 24 hour dose should not be administered at one time.

The maximum dosage for salmeterol has been stated according to the manufacturers’ recommendations.

• Category "S4. Hormone and metabolic modulators"
Androsta-3,5-diene-7,17-dione (arimistane) has been added as a new example of aromatase inhibitor.

• Category M1 "Manipulation of blood and blood components"
Supplemental oxygen administered by inhalation, but not intravenously, is permitted. To clarify this, M1.2 now reads “excluding supplemental oxygen by inhalation”.

• Category "S6. Stimulants"
Lisdexamfetamine has been added to S6.a; it is an inactive pro-drug of amfetamine.

• Category "S7. Narcotics"
Nicomorphine has been added. It is an opioid analgesic drug, which is converted to morphine following administration.

The full 2017 list, as well as a summary of all the changes, can be found on WADA's website